Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

Sanofi- Dealing with Stiff Competition in India from Three Acomplia Equivalents

It seems that Sanofi-Aventis’s acomplia still has to cross many barriers to make its way as three acomplia generics are giving tough competition to the anti-obesity drug in Indian market.

Acomplia generics launched by three Indian pharmaceuticals namely Sun Pharmaceuticals, Torrent Pharmaceutical and Zydus Cadila are making waves into the drug market and thus become a cause of worry for the anti-obesity drug.  Being recently launched, all three are benefiting from the fact that Indian legislation protects only those patents which are registered since 1995. And the patent for Acomplia's rimonabant molecule was indexed in 1994.

To deal with this stiff competition, Sanofi-Aventis is examining all available legal actions.
Meanwhile, Zydus is all set to introduce its generic equivalents in other countries wherein the legislation would not pose any hurdle in its way.

So far, Sanofi-Aventis has attained the FDA regulatory approval for Acomplia in many European countries and is waiting for the Food and Drug Administration (FDA) approval for sale in the U.S.